Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK117 plus azacitidine vs placebo plus azacitidine in treatment-naive higher-risk myelodysplastic syndromes
CTR20240085Phase 2Active
- Sponsor
- Akeso, Inc.
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ligufalimab in myelodysplastic syndrome (MDS), sponsored by Akeso, Inc.. Started Mar 2024; status: active.
02
Drugs
ligufalimab
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on CTR20240085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240085.